14 Facts About Sofosbuvir

Sofosbuvir, sold under the brand name Sovaldi among others, is a medication used to treat hepatitis C It is taken by mouth.

Sofosbuvir is in the nucleotide analog family of medications and works by blocking the hepatitis C NS5B protein.

Sofosbuvir was discovered in 2007 and approved for medical use in the United States in 2013.

Sofosbuvir is used with other medications and longer treatment durations, depending on specific circumstances, genotype and cost-effectiveness–based perspective.

Sofosbuvir allows most people to be treated successfully without the use of peginterferon, an injectable drug with severe side effects that is a key component of older drug combinations for the treatment of hepatitis C virus.

Related searches

Sofosbuvir used alone and in combination with other drugs such as ribavirin with or without a peginterferon has a good safety profile.

Sofosbuvir is a substrate of P-glycoprotein, a transporter protein that pumps drugs and other substances from intestinal epithelium cells back into the gut.

Sofosbuvir appears to have a high barrier to the development of resistance.

Sofosbuvir is a prodrug of the Protide type, whereby the active phosphorylated nucleotide is granted cell permeability and oral bioavailability.

Sofosbuvir is activated in the liver to the triphosphate GS-461203 by hydrolysis of the carboxylate ester by either of the enzymes cathepsin A or carboxylesterase 1, followed by cleaving of the phosphoramidate by the enzyme histidine triad nucleotide-binding protein 1, and subsequent repeated phosphorylation.

Sofosbuvir was discovered in 2007 by Michael Sofia, a scientist at Pharmasset, and the drug was first tested in people in 2010.

Sofosbuvir is on the World Health Organization's List of Essential Medicines.

Sofosbuvir is an excellent example of both the benefit and the challenge of specialty medications.

Sofosbuvir has been tested against other viruses such as the Zika virus and severe acute respiratory syndrome coronavirus 2 .